Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Tariffs and geopolitical disruption reshape global pharma supply chains, says GlobalData

New US tariff measures and acute geopolitical tensions are reshaping the global pharmaceutical landscape, prompting companies to rethink supply chains and production strategies, says GlobalData, a leading intelligence and productivity platform. A key driver is the US administration’s decision to impose tariffs on imported pharmaceuticals and their ingredients, upending decades of medicines trade orthodoxy. The […]
Read more

First CAR-T therapy Satri-cel for solid tumors positions China at forefront of next oncology revolution, says GlobalData

Solid tumors are emerging as the next frontier for CAR-T innovation, with China poised to deliver the world’s first approved CAR-T therapy for gastric cancer. The anticipated approval signals a pivotal shift in oncology treatment, expanding CAR-T beyond hematological malignancies and intensifying competition in the rapidly evolving solid tumor landscape, where early clinical success, regulatory […]
Read more

Progressive pulmonary fibrosis market to reach $2.7 billion across 7MM by 2035, forecasts GlobalData

The progressive pulmonary fibrosis (PPF) market across the seven major markets (7MM*) is forecast to grow from $1.3 billion in 2025 to $2.7 billion in 2035 at a compound annual growth rate (CAGR) of 7.6%, according to GlobalData, a leading intelligence and productivity platform. GlobalData’s latest report, “Progressive Pulmonary Fibrosis: Seven-Market Drug Forecast and Market […]
Read more

Meta-analysis backs broader use of blood pressure therapy in CKD, says GlobalData

Lowering blood pressure significantly reduces major cardiovascular events in chronic kidney disease (CKD) patients, with benefits matching those without CKD, according to a large meta-analysis. The findings challenge long-standing caution in advanced disease and support broader, earlier intervention. This evidence could reshape treatment strategies, expand antihypertensive use, and influence clinical guidelines across a growing, high-risk […]
Read more

Clinical trial recruitment remains key challenge in male infertility treatment, says GlobalData

Male infertility remains a difficult problem to treat, particularly because many patients and physicians prefer modern assisted reproductive technologies such as in vitro fertilization (IVF). A major reason for this difficulty is the limited clinical evidence and relatively sparse drug development focused on male-infertility therapies. Clinical data from randomized controlled trials (RCTs) is rare due […]
Read more

Auvelity provides breakthrough for treatment of Alzheimer’s agitation as first non-antipsychotic to be approved, says GlobalData

Following the news that the FDA has approved Axsome Therapeutics’ Auvelity (dextromethorphan + bupropion) for the treatment of agitation associated with dementia due to Alzheimer’s disease (AD); Philippa Salter, Managing Neurology Analyst at GlobalData, a leading intelligence and productivity platform, offers her view: “A major unmet need in the AD market is for treatments for […]
Read more

Non-dopaminergic strategy gains ground as solengepras shows promise in early Parkinson’s, says GlobalData

Solengepras has showed early promise in addressing Parkinson’s disease’s (PD) overlooked non-motor burden, with Phase II data highlighting meaningful improvements in sleep and related symptoms despite limited motor gains. This reinforces a strategic shift beyond dopamine-centric care, signalling growing industry focus on holistic disease management, where targeting non-motor pathways could redefine treatment priorities and unlock […]
Read more

Non-GLP-1 innovation intensifies competition in booming global obesity market, says GlobalData

The global obesity drug market is diversifying rapidly as non-glucagon-like peptide-1 receptor (GLP-1R) therapies gain momentum, signaling a structural shift beyond incretin-led growth. While GLP-1R agonists continue to dominate revenues, emerging mechanisms, particularly calcitonin receptor–targeting drugs, are set to accelerate expansion from 2028, intensifying competition, broadening treatment pathways, and prompting leading companies to strategically hedge […]
Read more

Azetukalner’s phase III success holds potential to change treatment paradigm for focal onset seizures, says GlobalData

At the 2026 American Academy of Neurology (AAN) meeting, Xenon Pharmaceuticals announced positive results from the Phase III X-TOLE2 study of azetukalner, a novel, potent, KV7 potassium channel opener, in focal onset seizures (FOS). The study evaluated the efficacy, safety, and tolerability of azetukalner, administered as an oral, adjunctive, once-daily therapy taken with food for […]
Read more

Venous thromboembolism diagnosed incident cases to reach 1.71 million across 7MM in 2034, forecasts GlobalData

The burden of diagnosed incident cases of venous thromboembolism (VTE) in the seven major markets (7MM*) is expected to increase at an annual growth rate (AGR) of 1.41% from 1.5 million in 2024 to 1.71 million cases in 2034, forecasts GlobalData, a leading intelligence and productivity platform. GlobalData’s latest report, “Venous Thromboembolism: Epidemiology Forecast to […]
Read more

Pharma firms accelerate regional capacity building to secure GLP-1 supply and mitigate geopolitical risks, reveals GlobalData

Regionalized glucagon-like peptide-1 (GLP-1) manufacturing investments and rising Middle East geopolitical disruptions are reshaping pharmaceutical supply strategies, pushing drugmakers to localize production, secure inventories, and build resilient Asia-focused capacity. The shift reflects intensifying demand for metabolic therapies and growing logistics risk, signaling a structural move toward geographically diversified manufacturing networks to protect launches, stabilize supply, […]
Read more

FDA-approved drug manufacturing deals shift to Europe, says GlobalData

In 2025, US contract manufacturing deals for FDA-approved drugs posted their steepest decline in five years. Despite record-high US tariffs on EU pharmaceuticals, biopharma companies, including US-based firms, are increasingly choosing to outsource manufacturing for the US market to facilities in Europe rather than shifting work to domestic providers, according to GlobalData, a leading intelligence […]
Read more

Biopharma catalysts in Q2 2026 signal high-profile approval decisions and rising competition, reveals GlobalData

An unclear outlook for Replimune’s BLA resubmission outlook for vusolimogene oderparepvec in advanced melanoma and debated clinical positioning for Arvinas’s vepdegestrant and Boehringer Ingelheim’s survodutide underscore intensifying competition across breast cancer and obesity therapeutics among other major catalysts are expected in Q2 2026, according to GlobalData, a leading intelligence and productivity platform. The FDA’s initial rejection […]
Read more

Longer-term real-world data needed to compare Leqembi and Kisunla opposing treatment strategies for Alzheimer’s, says GlobalData

In the current Alzheimer’s disease (AD) therapeutic space, the two approved disease-modifying therapies (DMTs) employ different treatment strategies, although both are anti-amyloid-beta (Aβ) monoclonal antibodies (mAbs). Eisai/Biogen’s Leqembi (lecanemab) is approved for continuous treatment until progression to moderate AD, whereas Eli Lilly’s Kisunla (donanemab) is being positioned as a finite treatment option that can be […]
Read more

Parkinson’s Awareness Month 2026: Alpha synuclein emerges as leading target in disease pipeline, says GlobalData

As Parkinson’s disease (PD) awareness month approaches this April, analysis of the global drug landscape reveals an evolving research focus in PD. While pharmaceutical research has historically concentrated on dopamine signaling, the current pipeline indicates increased interest in alpha synuclein as a therapeutic target, according to GlobalData, a leading intelligence and productivity platform. Most current […]
Read more

Late-stage pipeline to transform progressive pulmonary fibrosis treatment landscape, says GlobalData

Progressive pulmonary fibrosis (PPF) describes a phenotype of non-idiopathic pulmonary fibrosis (IPF) interstitial lung diseases (ILDs) that continues to worsen despite appropriate management, leading to lung scarring, loss of lung function, and early mortality. Current antifibrotic agents slow the rate of forced vital capacity (FVC) decline but do not halt or reverse fibrosis, leaving substantial […]
Read more

Sasineprocel’s future lies as a monotherapy in Parkinson’s disease, says GlobalData

Sasineprocel’s encouraging Phase I/IIa data positions autologous iPSC-derived dopaminergic neuron therapy as a potential monotherapy challenger in Parkinson’s disease (PD), signaling a shift toward regenerative treatment strategies beyond symptomatic dopamine replacement. Strong safety, graft survival, and functional improvements underscore its disruptive promise, though cost, reimbursement hurdles, and upcoming Phase III validation will determine its real-world […]
Read more
1 2 3 4 5 6 … 110